Cancer is the most common cause of death worldwide. Annually, more than ten million new cancer cases are diagnosed, and more than six million deaths occur due to cancer. Nonetheless, over 80% of human cancer may be preventable through proper nutrition. Numerous nutritional compounds are effective in preventing cancer. Selenium and zinc are essential micronutrients that have important roles in reducing oxidative stress and protecting DNA from the attack of reactive oxygen species. Selenium is an essential trace element that possesses several functions in many cellular processes for cancer prevention. Meanwhile, zinc may have protective effects on tumor initiation and progression, and it is an essential cofactor of several mammalian proteins. Results show that both selenium and zinc provide an effective progression of DNA repair system; thus, cancer development that originated from DNA damage is decreased. Results mostly focus on the separate effects of these two elements on different cell types, tissues, and organs, and their combined effects are largely unknown. This review aimed to emphasize the joint role of selenium and zinc specifically on DNA repair for cancer prevention.
Cause of Death ; DNA Damage ; DNA Repair ; DNA ; Humans ; Joints ; Micronutrients ; Oxidative Stress ; Reactive Oxygen Species ; Selenium ; Trace Elements ; Zinc

Objective: To evaluate long-term effects of COVID-19, and to determine the risk factors in long-COVID in a cohort of the Turkish Thoracic Society (TTS)-TURCOVID multicenter registry. Methods: Thirteen centers participated with 831 patients; 504 patients were enrolled after exclusions. The study was designed in three-steps: (1) Phone questionnaire; (2) retrospective evaluation of the medical records; (3) face-to-face visit. Results: In the first step, 93.5% of the patients were hospitalized; 61.7% had a history of pneumonia at the time of diagnosis. A total of 27.1% reported clinical symptoms at the end of the first year. Dyspnea (17.00%), fatigue (6.30%), and weakness (5.00%) were the most prevalent long-term symptoms. The incidence of long-term symptoms was increased by 2.91 fold (95% CI 1.04-8.13, P=0.041) in the presence of chronic obstructive pulmonary disease and by 1.84 fold (95% CI 1.10-3.10, P=0.021) in the presence of pneumonia at initial diagnosis, 3.92 fold (95% Cl 2.29-6.72, P=0.001) of dyspnea and 1.69 fold (95% Cl 1.02-2.80, P=0.040) fatigue persists in the early-post-treatment period and 2.88 fold (95% Cl 1.52-5.46, P=0.001) in the presence of emergency service admission in the post COVID period. In step 2, retrospective analysis of 231 patients revealed that 1.4% of the chest X-rays had not significantly improved at the end of the first year, while computed tomography (CT) scan detected fibrosis in 3.4%. In step 3, 138 (27.4%) patients admitted to face-to-face visit at the end of first year; at least one symptom persisted in 49.27% patients. The most common symptoms were dyspnea (27.60%), psychiatric symptoms (18.10%), and fatigue (17.40%). Thorax CT revealed fibrosis in 2.4% patients. Conclusions: COVID-19 symptoms can last for extended lengths of time, and severity of the disease as well as the presence of comorbidities might contribute to increased risk. Long-term clinical issues should be regularly evaluated after COVID-19.